Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 1/2 2Phase 1 2Phase NA 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 37NIH 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Dermatologic 1

Conditions

Melanoma 1Hematologic Neoplasms 1

Interventions

Specimen Handling 95Biopsy 79Magnetic Resonance Spectroscopy 74Paclitaxel 56Cyclophosphamide 53Cisplatin 53Radiotherapy 51Carboplatin 50Gemcitabine 43Bortezomib 38Irinotecan 37Taxes 32Fluorouracil 32Radiation 30veliparib 29Filgrastim 29Doxorubicin 29Vorinostat 27Oxaliplatin 27Leucovorin 27Ipilimumab 27alvocidib 26Cytarabine 26Temozolomide 25aldesleukin 24Rituximab 24fludarabine 23Etoposide 23Decitabine 23temsirolimus 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × NIH × Whole-Body Irradiation × Clear all
NCT07162038 2026-06-05

Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
155 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

NCT00091104 2012-03-15

Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
136 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡